Orgovyx, Nubeqa, & Early Taxotere | 2021 Treatments In Review | Mark Scholz, MD скачать в хорошем качестве

Orgovyx, Nubeqa, & Early Taxotere | 2021 Treatments In Review | Mark Scholz, MD

PCRI's Alex asks medical oncologist, Mark Scholz, MD, to give a survey of the changes in prostate cancer care in 2021. Dr. Scholz discusses the approval of Orgovyx, the new indication for Nubeqa, and a study that showed a greater benefit from earlier use of Taxotere in patients with metastatic disease. 0:09 Orgovyx (relugolix), a new form of hormone therapy, was recently approved in the treatment of prostate cancer. Can you explain how it is different from existing forms of hormone therapy like Lupron, Firmagon, Trelstar, etc.? 3:40 Nubeqa (darolutamide) was previously approved in men with castrate-resistant non-metastatic disease, but it was recently approved in a new segment of prostate cancer patients in 2021. Can you explain that and what it means for patients? 6:13 A trial was presented in 2021 that demonstrated a greater benefit from earlier use of Taxotere (a form of chemotherapy). Can you explain more about that and which patients should be considering earlier use of Taxotere? Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org To learn more about prostate cancer visit http://www.pcri.org Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: https://pcri.org/join Who we are: The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors. The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs. #ProstateCancer #Prostate #MarkScholzMD